Disease-Modifying Therapy, Quantitative Imaging, and AI for Managing Patients with Alzheimer Disease

In this discussion, Dr Tanenbaum and Suzie Bash, MD, a Medical Director at RadNet in Los Angeles, cover the intersection of disease-modifying therapies (DMTs), quantitative imaging, and artificial intelligence (AI) in managing Alzheimer disease.

Creators and Guests

Host

Lawrence Tanenbaum, MD, FACR

Dr. Tanenbaum is a long term collaborator with the medical imaging industry, with interests in developing applications of contrast agents, MR, CT and advanced rendering in the clinical practice of medicine focusing on efficiency, radiation dose appropriateness and physiologic imaging. Dr. Tanenbaum has authored approximately 100 scholarly and peer reviewed articles, continues to chair educational and academic meetings and has delivered over 1500 invited lectures around the world.

Guest

Suzie Bash, MD

Neuroradiologist. Interested in Artificial Intelligence (AI) applications in advanced Neuroimaging, MRI, FDG brain PET/CT, Amyloid PET, Dementia, Multiple Sclerosis (MS), Quantitative Volumetric MRI (QMRI), Deep Learning Image Reconstruction (DLR), Clinical Research, DL, ML, Medicine, CT, Digital Imaging, Neuroradiology, and music.

What is Trends in Alzheimer Imaging & Management?

Moderated by Lawrence Tanenbaum, MD, FACR, Applied Radiology hosted a series of conversations with experts in Alzheimer disease imaging and management at the 2024 Radiological Society of North America Annual Meeting and Scientific Exhibition.